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to block the transmission of Babesia canis by
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Frederic Beugnet1*, Lenaig Halos1, Diane Larsen1, Michel Labuschagné2, Heidi Erasmus2 and Josephus Fourie2Abstract
Background: Canine babesiosis due to Babesia canis is an endemic disease in many European countries. A vaccine
is available in some countries, but it does not prevent the infection and just helps in reducing the gravity of clinical
signs. Therefore, the major way to help preventing the disease is by controlling tick infestations on dogs.
To assess the preventive efficacy of afoxolaner (NexGard®), a new oral anti- flea and tick product, against Babesia
canis infected adult Dermacentor reticulatus in an experimentally controlled study.
Methods: Sixteen healthy mixed breed adult dogs, negative for Babesia canis antibodies were included in a single
centre, randomized, blinded and controlled study to evaluate the impact of treatment with afoxolaner on the
transmission of Babesia canis to dogs exposed to Dermacentor reticulatus. The dogs were randomly allocated into
two groups of 8 dogs each. One group remained untreated. In the other group, dogs were treated orally with a
novel formulation of afoxolaner (NexGard®) on day 0. All dogs were infested each by 50 adult Dermacentor
reticulatus ticks (equal sex ratio) at days 7, 14, 21 and 28. The Dermacentor reticulatus ticks were confirmed to
harbour Babesia canis by Polymerase Chain Reaction (PCR).
Results: The treatment was well tolerated by all dogs without any adverse effects. Babesia canis was transmitted
by D. reticulatus to all untreated control dogs, confirmed following demonstration of hyperthermia, detection of
B. canis parasites in blood smears and PCR assay from blood and serology. These confirmed infected dogs were
subsequently treated with imidocarb and diminazene. The treated dogs remained negative based on all criteria
until the last study, Day 56, confirming that the oral treatment of dogs with NexGard® prevented transmission of
Babesia canis and development of clinical babesiosis for up to 28 days.
Conclusion: This is the first demonstration that an oral acaricidal treatment may prevent the transmission of a
pathogen despite the need for the tick to attach and start feeding before being killed by the acaricide.
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Ticks are endemic throughout Europe with more than
twelve different species, of varying biology and geo-
graphic distribution [1]. Ixodes ricinus and Dermacentor
reticulatus commonly infest dogs and are vectors of
various canine vector borne pathogens including Bor-
relia burgdorferi and Anaplasma phagocytophilum, both
transmitted by I. ricinus, and Babesia canis transmitted
by D. reticulatus [1,2]. D. reticulatus is widely distributed* Correspondence: Frederic.beugnet@merial.com
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environmental conditions [3]. Its distribution has been
expanding in Europe [3-6]. The period of tick activity is
also increasing in Europe. For example, the total duration
of Dermacentor questing activity over the year as well as
its presence in winter was shown to increase in Belgium,
Switzerland, Poland, Germany, Slovenia and Slovakia
[1,7-9]. Climate change is one of the factors which could
explain the change in distribution and in activity amongst
many others such as land use and host distribution [8,9].
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logically distinct groups, the larger Babesia canis and the
smaller Babesia gibsoni. B. canis has been reclassified
into three sub-species (B. canis canis, B. canis rossi and
B. canis vogeli) on the basis of vector-specificity and
cross-immunity and are now considered to be separate
species, B. canis, B. rossi and B. vogeli [10-12]. However,
both species and sub-species names remain in use in the
current literature. Babesia canis is widely distributed
throughout Europe, where it is transmitted by adult
Dermacentor reticulatus ticks [13-17]. France is the
most endemic country in Europe [18,19]. The clinical
signs of babesiosis in dogs vary from a mild transient ill-
ness to acute disease due to severe haemolysis that rap-
idly results in death. Clinical findings include anorexia,
pale mucous membranes, icterus, pyrexia, and splenic
enlargement.
Published studies demonstrating the utility of tick con-
trol compounds on dogs have been focused on their
acaricidal efficacy against a broad range of ixodid tick
species [20]. Some experimental studies have shown
the protective effect provided by topical insecticide/
acaricide. Efficacy is based on repellent/irritant effect by
contact, inhibition of attachment and blood meal, and/or
a quick speed of kill [21]. The protective effect of an acar-
icidal molecule given orally to dogs and acting systemic-
ally is less obvious as the ticks must attach and start to
feed before being killed. Nevertheless, it has been demon-
strated that pathogens need some time to be transmitted
[1]. Nevertheless, an acaricide may cause rapid death
after ingestion and or block feeding physiology of the
tick. The present study describes the results of an experi-
mental study to assess the efficacy of afoxolaner, a new
insecticide-acaricide administered orally in a soft chew-
able formulation (Nexgard®, Merial), against D. reticula-
tus infected with Babesia canis in dogs. Afoxolaner
belongs to a new class of insecticides-acaricides, the
isoxazoline [22], acting systemically through oral for-
mulation [23]. Afoxolaner is highly bound to plasmatic
proteins and it is ingested by the hematophagous arthro-
pods during their blood meal. It acts as a ligand to a spe-
cific receptor on both GABA and glutamate receptors on
the ion chloride channel in the neuron synapses. It in-
duces hyperexcitation before death of both fleas and ticks.
The new oral formulation, NexGard®, has been proven to
control flea and tick infestation (Ixodes, Dermacentor and
Rhipicephalus) for a month on dogs [24].
Methods
Study design
The study was conducted according to the International
Cooperation on Harmonization of Technical Require-
ments for Registration of Veterinary Medicinal Products
Guideline 9: Good Clinical Practice, and in compliancewith South African animal welfare legislation. The study
employed a controlled, blinded, randomized block de-
sign and utilized adult, healthy, mongrel dogs. All dogs
were individually penned in tick-proof kennels, were
managed similarly and observed once daily for health
abnormalities throughout the study. When health ab-
normalities were detected between the scheduled physical
examinations, additional examinations were conducted. In
order to control bias, the animals were not treated by a
person involved in performing the post-administration as-
sessments and observations.
Two groups of 8 dogs were included, one untreated
control and one NexGard® (Merial) treated group. The
treatment was administered on Day 0. All dogs were
infested by ticks on Days 7, 14, 21 and 28. The ticks were
not removed and counted until Day 30. The dogs were
blood sampled on Days −7, 14, 21, 28, 35, 42, 49, 56. At
Day 56, the last study day, dogs were removed from their
boxes and put back to their original runs. In order to check
the maintenance of seropositivity in the infected dogs, a
blood sample was taken for serology on Day 93.
Animals
On Day −1, body weight of each dog was used for rank-
ing and group allocation purposes. The study followed
a randomised block design. The 16 dogs included on
Day −7 were ranked, within sex, in descending order
of individual body weight. Within each block, dogs
were randomly allocated to groups 1 or 2. The dogs were
clinically healthy as verified by a veterinarian on Day −7;
they were older than 2 months; they weighed 11.97 kg to
21.43 kg; the females were not pregnant; and they had not
been treated with a long acting topical or systemic acari-
cide/insecticide during the 12 weeks preceding Day −7. All
the animals were observed daily from Days −7 to 56.
They were tested PCR negative and sero-negative
(IFAT) for Babesia canis on Day −7 at the start of
acclimatization. They were then maintained individually in
cages in a controlled tick free zone where all experimental
tick studies are conducted, in order to avoid any external
contamination.
During the study, the dogs were examined clinically
daily to detect any signs of canine babesiosis including
body temperature > 39.4°C.
In addition to scheduled blood samples, a tem-
perature > 39.4°C was the trigger for collection of a
blood sample, an immediate blood smear and a PCR.
All dogs confirmed positive for Babesia by blood smear
received the appropriate treatment with imidocarb
(Forray® 65) and diminazene (Berenil® RTU). By experience,
the combination of imidocarb and diminazene is chosen to
allow a single treatment without repeat treatment 14 days
later, and to minimize the risk of relapse. Tick challenges
were discontinued for these animals.
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free kennel, environmentally controlled for temperature
(20 ± 4°C). The study animals were kept individually in
cages and no direct contact between dogs was possible
during the study.
Treatment
Eight dogs were treated on Day 0 with NexGard®, an oral
formulation of 2.27% w/w afoxolaner. They were dosed
orally by giving a palatable chew by hand. They all
ingested the chew spontaneously when offered. All dogs
weighed between 10.1 to 25 kg and received the 3 g
chew containing 68 mg afoxolaner. No vomiting was ob-
served and none of the animals was redosed.
Tick challenges
A laboratory-bred Dermacentor reticulatus tick strain
infected with Babesia canis was used for the chal-
lenges. The Dermacentor reticulatus strain is main-
tained on dogs and derived from wild ticks collected
in Europe. The D. reticulatus ticks were infected
with B. canis by feeding them on dogs previously in-
fected intravenously by with a B. canis strain originated
from France. The Babesia strain was firstly isolated
from a D. reticulatus female collected from a dog in
France. It is conserved in frozen EDTA dog blood and
injected to dogs when needed for maintenance or to
initiate studies.
A sample of 50 D. reticulatus ticks was taken weekly
from the batch of ticks to be used for challenges and the
infectivity was tested and confirmed by PCR analysis be-
fore the infestation of the dogs (Table 1). All dogs were
infested with 50 ticks each on Days 7, 14, 21 and 28.
Adult ticks, which were used in the challenges, were un-
fed, at least one week old and had a balanced sex ratio
(50% female: 50% male). For logistic reason, the tick in-
festations of the second week were split between Day 14
and Day 15.
Ticks were applied directly on the dog by tapping
the vial to dislodge the ticks from the container so
that they could be placed or spread directly over the
dog’s hair coat. Gloved fingers were used to facilitate
hair penetration by ticks once placed on the animal.
Dogs were placed for approximately four hours in an
infestation crate to enhance tick attachment, then they
were placed again in their individual box. Ticks dis-
lodged during the first 10 minutes were placed back on
the dog.Table 1 Results of the weekly Babesia canis PCR on 50 ticks
from the batch used for dog infestations
Day 7 Day 14 Day 21 Day 28
PCR results 10% 10% 8% 10%Tick removal and count
The ticks were removed and counted on dogs diagnosed
for babesiosis and on all remaining dogs on Day 30.
They were categorized as free or attached and dead or
alive, following WAAVP recommendation [25].
Blood collection and blood smear for Babesia canis
detection
In addition to scheduled blood samples, a blood sam-
ple was collected and a blood smear prepared in case
of clinical suspicion of Babesia infection (body tem-
perature > 39.4°C). Blood sampling was realized on the
cephalic vein of the arm. Blood was collected for PCR ana-
lysis and serology from all dogs diagnosed with babesiosis
(on the day of diagnosis, before rescue treatment) based
on blood smears and from all dogs on Days - 7, 14, 21,
28, 35, 42, 49, 56. A Day 93 post-study sample was
taken on all dogs to check the maintenance of the sero-
logical status.
Three-milliliter blood samples were collected in EDTA
tubes for PCR analysis. Prior to starting the procedure,
approximately 1 mL of blood was taken from the 3 mL
whole blood sample and stored in a cryo tube in a −80°C
freezer (<70°C), which served as a secondary sample for
PCR analysis. The remaining 2 mL whole blood sam-
ples were transferred to the ClinVet molecular laboratory
for analysis. Total DNA was isolated from individual ticks
(for batch infectivity determination and verification) and
200 μl whole blood (for diagnostic purposes) using a
commercially available DNA isolation kit. Up to 400 ng
isolated DNA served as template in a PCR assay based
on targeting 18 S rRNA ITS-1 gene regions originally
identified by Duarte et al. [26]. The following primers:
Babesia canis 2F (5′-GGAAGGAGAAGTCGTAACAA
GGTTTCC-3′) and B.canis 2R (5′-CAGTGGTCACA
GACCGGTCG-3′) were used. They are species specific
and there is no cross-reaction with Babesia vogeli and
Babesia rossi. The PCR method was developed and tested
prior to the study at ClinVet. Babesia species have 2 to 5
copies of the rDNA targeted region present per genome
[27]. Each set of species specific primers was tested
against two individually confirmed cases each for B. canis
and B. vogeli and one confirmed and one suspected case
of B. rossi. During this study, each PCR run included a
positive control, negative control and a no template con-
trol. An internal amplification control was employed to
validate each PCR reaction success in order to eliminate
false negatives. The presence of an approximately 300 bp
PCR product, subsequent to agarose gel electrophoresis,
confirmed detection of Babesia canis DNA in the sample.
The obtained PCR products were processed for sequence
analysis. Both strands were completely sequenced and as-
sembled sequence data was subjected to BLAST analysis
where a 100% identity was obtained towards known
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AF394533) as well as the Babesia canis originally used for
donor animal infection and then to infect the D. reticulatus
tick vector.
Another 3 mL of blood was collected from each dog
for serology. Serum was recovered from the plain tubes
and divided into primary and duplicate aliquots. Primary
aliquots were stored at 2°C to 8°C for two days until
assayed for Babesia canis antibodies, using a commercial
IFA test carried out as described by Uilenberg et al. [10].
Duplicate aliquots were frozen at < −35°C. For screening
purposes the sera were diluted at 1:80 and results were
expressed as positive (fluorescence at dilution 1:80) or
negative (no fluorescence). One positive IFA result was
considered sufficient and therefore testing of serum was
discontinued after a first positive result on a dog. Never-
theless a post-study Day 93 serology was performed on a
blood sample from each dog.
Effectiveness assessment
The primary assessment criterion was the number of
dogs infected with Babesia canis in the control and
treated group.
Statistical analysis
An efficacy failure (successful infection with Babesia)
was regarded as a dog in the Nexgard® treated group that
was tested serologically positive for Babesia canis anti-
bodies or tested positive for Babesia canis by PCR analysis
or tested positive by blood smear direct examination.
The infection rate was calculated in the treated group
at the end of the study, Day 56, and was compared sta-
tistically with that of the control group.
The percentage blocking efficacy was calculated as
follows:
Efficacy %ð Þ ¼ 100 Tc−Ttð Þ=Tc;
where: Tc = Total number of infected dogs in the nega-
tive control groupTt = Total number of infected dogs in
the NexGard® administration group.
The proportion of animals infected in each group was
also compared using the chi-square test or Fisher’s exact
test as applicable. SAS® Version 9.3 TS Level 1 M2 was
used for all the statistical analyses. The level of signifi-




A sample of 50 D. reticulatus ticks was taken from the
batch of ticks to be used for each artificial challenge and
the infectivity confirmed by PCR analysis. Results of
the PCR analysis indicated that 8 – 10% of ticks wereBabesia infected (Table 1). The arithmetic mean tick
counts recorded for the untreated control group 1 was
15.0 at Day 9 and 41.1 on Day 16, indicating a vigorous
tick challenge.
Blood smear evaluation results
In addition to scheduled blood smears at the start of the
study, blood smears were prepared and examined for the
presence of B. canis sporozoites for all dogs with pyrexia
(>39.4°C) from Day 7 onwards after first tick infestation
(Table 2). Babesia canis sporozoites were observed on
blood smears from all dogs in the untreated control group
on at least one occasion. No parasites were observed on
any of the blood smears from the treated dogs.
Tick counts and tick count efficacy data
Live ticks were present on all control dogs at the time
they were diagnosed positive for Babesia (Day 15 – 16)
(Table 2). Infestations were relatively high (8 – 67 ticks).
In contrast, only a few dead ticks (0 – 6) were observed
on treated dogs on Day 30 at the end of tick phase of
the study. This reinforces the efficacy of afoxolaner
against Dermacentor reticulatus ticks (Table 3). The
count and the categorization of ticks on the treated
dogs showed that only a few dead attached ticks were
observed.
Babesia canis infection
All dogs in the untreated control group were positive for
babesiosis based on blood smear and PCR analysis.
Seven out of the eight control dogs became serologically
positive on Day 21 and remained positive until the last
study Day 56 (Table 4). All control dogs were Babesia
infected after the two tick infestations on Day 7 or
Day 14/15. None of the dogs in the treated group was
positive for babesiosis on blood smear, IFAT or PCR
analysis during the 56 days of the study. Nexgard®
treatment was therefore regarded to be fully effective
in preventing the transmission of Babesia canis by in-
fected Dermacentor reticulatus ticks (100% preventive
efficacy, p = 0.0014).
At Day 93, the 7 seropositive control dogs were still
positive. Surprisingly, one previously negative treated
dog was found slightly positive by IFAT (considered
positive by one examiner and negative by another). PCR
and blood smear were negative. This particular dog was
negative for blood smear, PCR and serology throughout
the study until day 56 and did not show any clinical
signs of infection.
Discussion
Conduct of this study required the generation of a large
batch of ticks with an adequate Babesia infection rate.
The rates of infection calculated by PCR on ticks were
Table 2 Results of blood smear examination of dogs having a temperature > 39.4°C on a daily observation
Group
Body temp range (°C) Blood smear preparation and examination day
Min Max 14 15 20 21 25 26 28 29 35 42 49
1
38.0 40.8 NEG POS - - - - - - - - -
37.7 39.7 - POS - - - - NEG - NEG - -
38.0 39.6 POS NEG - - - - - - NEG NEG -
38.1 39.8 POS NEG - - - - - - - NEG -
38.2 39.8 - POS - - - - - - - - -
37.0 40.4 NEG POS - - - - - - - - -
38.2 39.5 - POS - - - - - - - NEG -
37.5 40.4 NEG POS - - - - - - - - -
2
37.6 39.5 - - - NEG NEG - - - - NEG -
37.5 39.2 - - - - - - - - - NEG -
37.9 40.0 NEG NEG NEG - - - NEG - - NEG NEG
38.0 39.3 - - - - - - - - - - -
37.8 41.3 NEG NEG NEG NEG - - NEG - NEG NEG NEG
38.1 39.4 - - - - - - NEG - NEG NEG -
37.9 39.4 - - - - - - NEG - - - -
37.6 40.1 NEG NEG NEG - - NEG NEG NEG NEG NEG NEG
Positive results are in bold.
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scribed by Fourie et al. [28] assessing the efficacy of
the combination of fipronil-amitraz-(S)-methoprene
(Certifect®). Regardless of which sex or if both sexes











15 Control 0 0 32 35
15 Control 0 0 28 31
16 Control 1 0 16 15
16 Control 0 0 25 24
16 Control 0 0 17 18
16 Control 0 0 24 24
16 Control 0 0 6 10
16 Control 0 0 16 16
30 Treated 0 0 0 0
30 Treated 0 0 0 0
30 Treated 0 0 0 0
30 Treated 0 0 0 0
30 Treated 0 0 0 0
30 Treated 0 0 0 0
30 Treated 0 0 0 0
30 Treated 0 0 0 0
*Study day where the dogs were removed due to canine babesiosis; or Day 30, 48
Tick numbers are indicated in bold when it is >0.was sufficiently high to successfully transmit the infection
to 8 out of 8 untreated (control) dogs. All untreated dogs
were infected and were rescue treated immediately after
diagnosis. The early treatment can explain the absence










0 0 0 0
0 0 0 0
2 0 0 0
1 0 1 0
0 0 0 0
0 0 2 0
2 0 1 1
0 1 0 0
2 3 0 0
1 1 0 0
2 2 0 1
0 1 0 0
0 0 2 0
3 2 1 0
0 0 1 0
0 0 0 0
h after the last tick infestation.
Table 4 Summary of assessment for B. canis infection
Group
- 7 14/15 +21 +28 +35 +42 +49 +56 (last study Day) + 93
IFAT IFAT PCR IFAT PCR IFAT PCR IFAT PCR IFAT PCR IFAT PCR IFAT PCR IFAT
Control
NEG NEG POS POS POS POS NEG NEG NEG NEG POS
NEG NEG POS POS NEG NEG NEG NEG NEG NEG POS
NEG NEG POS POS NEG NEG NEG NEG NEG NEG POS
NEG NEG POS POS NEG NEG NEG NEG NEG NEG POS
NEG NEG POS POS NEG NEG NEG NEG NEG NEG POS
NEG NEG POS POS POS NEG NEG NEG NEG NEG POS
NEG NEG POS NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG
NEG NEG POS POS NEG NEG NEG NEG NEG NEG POS
Treated
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG +/− POS*
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG
*This dog did not show any clinical signs, and remained Blood smear, PCR and serology negative until the end of the study (Day 56). He was found to be positive
by one examiner at Day 93, showing a diffuse fluorescence including dog cells and some Babesia canis, which was considered as negative by another examiner.
Positive results and final check at Day 56 and Day 93 are indicated in bold.
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possibly explains that one control dog, despite a positive
blood smear and PCR remained serologically negative.
Regarding the treated dog that possibly seroconverted on
Day 93 post-study, as all dogs were moved back to their
community runs on Day 56, it is not known whether it is a
late seroconversion, a more recent infection that appeared
after the study, or a false positive fluorescence due to an-
other reason.
Protozoan parasites require additional time, usually
several days, for their sporoblasts to mature into sporo-
zoites in the salivary glands of the tick before they can
be secreted into the saliva and transmitted to the mam-
malian host. For instance, Babesia microti is transmitted
by Ixodes scapularis between 36 and 48 hours after tick
attachment [29]. The treatment assessed here is an oral
formulation, meaning that ticks need to attach and start
to feed before being killed. Afoxolaner efficacy against
Dermacentor reticulatus has been demonstrated for a
full month [24] with ticks evaluated at 48 hours after
each infestation. The protection against the transmission
of Babesia canis demonstrated in this study is a conse-
quence of the time needed for ticks to transmit Babesia.
It may also be due to the action of afoxolaner on the tick
feeding physiology or on the rapid tick death. The fact
that no live ticks were found at Day 28 and very few at-
tached ticks is suggestive of a quick death but also de-
tachment, which may also impact on the transmission
of Babesia. Another study involving the combination ofFipronil-amitraz-(S)-methoprene demonstrated 86% effi-
cacy against transmission using a similar protocol [21].
This topical formulation is known to induce a quick
death, in less than 24 h and a detachment or a preven-
tion of attachment of ticks [30].
Conclusion
The oral formulation of afoxolaner demonstrated in this
experimental study a complete efficacy in preventing the
transmission of Babesia canis.
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